NanoVibronix Inc (NAOV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NanoVibronix Inc (NAOV) has a cash flow conversion efficiency ratio of -0.046x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.97 Million) by net assets ($42.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see NAOV market cap overview for the company's overall valuation and market capitalisation.
NanoVibronix Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how NanoVibronix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
NanoVibronix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NanoVibronix Inc ranked by their cash flow conversion efficiency. Explore NanoVibronix Inc (NAOV) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Innity Corporation Bhd
KLSE:0147
|
-0.154x |
|
Sawang Export Public Company Limited
BK:SAWANG
|
0.001x |
|
Moolec Science SA Ordinary Shares
NASDAQ:MLEC
|
-0.059x |
|
Mamba Exploration Ltd
AU:M24
|
-0.144x |
|
CPPGroup Plc
F:4CV1
|
-2.851x |
|
Vsolar Group Bhd
KLSE:0066
|
-0.071x |
|
Neola Medical AB
ST:NEOLA
|
-0.025x |
|
IDOX plc
LSE:IDOX
|
0.002x |
Annual Cash Flow Conversion Efficiency for NanoVibronix Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of NanoVibronix Inc from 2011 to 2024. View latest NanoVibronix Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $627.00K | $-2.52 Million | -4.013x | -344.28% |
| 2023-12-31 | $3.99 Million | $-3.60 Million | -0.903x | +58.49% |
| 2022-12-31 | $3.23 Million | $-7.04 Million | -2.176x | -214.57% |
| 2021-12-31 | $6.31 Million | $-4.37 Million | -0.692x | +51.16% |
| 2020-12-31 | $2.39 Million | $-3.39 Million | -1.416x | +50.71% |
| 2019-12-31 | $1.35 Million | $-3.87 Million | -2.874x | +62.52% |
| 2018-12-31 | $463.00K | $-3.55 Million | -7.667x | -1176.96% |
| 2017-12-31 | $3.63 Million | $-2.18 Million | -0.600x | -197.88% |
| 2016-12-31 | $-2.50 Million | $-1.53 Million | 0.613x | -91.34% |
| 2015-12-31 | $-209.00K | $-1.48 Million | 7.081x | +4318.76% |
| 2014-12-31 | $-5.62 Million | $-900.00K | 0.160x | -12.23% |
| 2013-12-31 | $-3.30 Million | $-602.00K | 0.183x | -57.50% |
| 2012-12-31 | $-1.83 Million | $-787.00K | 0.430x | -54.06% |
| 2011-12-31 | $-585.00K | $-547.00K | 0.935x | -- |
About NanoVibronix Inc
NanoVibronix, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increa… Read more